Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Author(s): Xinyu Shen, Minglan Yang, Hua Xu, Huan Zhou, Liwei Wang and Jing Ma*

DOI: 10.2174/1871530323666221208111823

DownloadDownload PDF Flyer Cite As
Immunotherapy-Associated Hypophysitis under Anti-PD1: Two Case Reports

Page: [996 - 1004] Pages: 9

  • * (Excluding Mailing and Handling)

Abstract

Background: Immunotherapy-associated hypophysitis is an uncommon adverse event. However, if not handled properly, it could lead to fatal sequelae.

Case Presentations: Case 1. A 66-year-old man presented to our hospital with hyponatremia. He had low plasma levels of adrenocorticotropin and cortisol. The patient had a history of non-small cell lung cancer and had undergone 16 cycles of immunotherapy with sintilimab, a monoclonal antibody against programmed cell death protein 1 (PD1). He was diagnosed with adrenal insufficiency secondary to immunotherapy-associated hypophysitis and received a physiological dose of glucocorticoids. Upon discharge, he has prescribed a continued course of hormone replacement therapy combined with immunotherapy. Case 2. The second case profiled here involved a 58- year-old patient diagnosed with gastric antrum cancer. After ten months of immunotherapy with carrelizumab, a human high-affinity immunoglobulin G4 (IgG4) anti-PD-1 monoclonal antibody drug, the patient was referred to the Endocrinology Department at our medical centre for adrenal nodules and intolerance of anorexia. He also suffered from hypophysitis and was prescribed hormone replacement therapy combined with immunotherapy.

Conclusion: This article discusses the clinical characteristics, diagnosis, treatment, and subsequent follow-up for immunotherapy-associated hypophysitis in the context of two case reports. Based on our findings and observations, we conclude that patients with immunotherapy should regularly be referred to endocrine-related follow-up during tumour treatment.

Graphical Abstract

[1]
Zhou, N.; Velez, M.A.; Owen, D.; Lisberg, A.E. Immune-Related Adverse Events (irAEs): Implications for immune checkpoint inhibitor therapy. J. Natl. Compr. Canc. Netw., 2020, 18(9), 1287-1290.
[http://dx.doi.org/10.6004/jnccn.2020.7640] [PMID: 32886906]
[2]
Kobayashi, T.; Iwama, S.; Yasuda, Y.; Okada, N.; Okuji, T.; Ito, M.; Onoue, T.; Goto, M.; Sugiyama, M.; Tsunekawa, T.; Takagi, H.; Hagiwara, D.; Ito, Y.; Suga, H.; Banno, R.; Yokota, K.; Hase, T.; Morise, M.; Hashimoto, N.; Ando, M.; Fujimoto, Y.; Hibi, H.; Sone, M.; Ando, Y.; Akiyama, M.; Hasegawa, Y.; Arima, H. Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: A prospective study. J. Immunother. Cancer, 2020, 8(2), e000779.
[http://dx.doi.org/10.1136/jitc-2020-000779] [PMID: 32606047]
[3]
Carpenter, K.J.; Murtagh, R.D.; Lilienfeld, H.; Weber, J.; Murtagh, F.R. Ipilimumab-induced hypophysitis: MR imaging findings. AJNR Am. J. Neuroradiol., 2009, 30(9), 1751-1753.
[http://dx.doi.org/10.3174/ajnr.A1623] [PMID: 19474123]
[4]
Weber, J.S.; Postow, M.; Lao, C.D.; Schadendorf, D. Management of adverse events following treatment with anti-programmed death-1 agents. Oncologist, 2016, 21(10), 1230-1240.
[http://dx.doi.org/10.1634/theoncologist.2016-0055] [PMID: 27401894]
[5]
Arima, H.; Iwama, S.; Inaba, H.; Ariyasu, H.; Makita, N.; Otsuki, M.; Kageyama, K.; Imagawa, A.; Akamizu, T. Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: Clinical guidelines of the Japan Endocrine Society. Endocr. J., 2019, 66(7), 581-586.
[http://dx.doi.org/10.1507/endocrj.EJ19-0163] [PMID: 31243183]
[6]
Yamauchi, I.; Taura, D.; Hakata, T.; Fujita, H.; Okamoto, K.; Ueda, Y.; Fujii, T.; Inagaki, N. Clinical features and thyroid dysfunction in adverse events involving the pituitary gland during PD‐1 blockade therapy. Clin. Endocrinol., 2021, 94(2), 258-268.
[http://dx.doi.org/10.1111/cen.14349] [PMID: 33037658]
[7]
Faje, A. Immunotherapy and hypophysitis: Clinical presentation, treatment, and biologic insights. Pituitary, 2016, 19(1), 82-92.
[http://dx.doi.org/10.1007/s11102-015-0671-4] [PMID: 26186958]
[8]
Ishihara, R.; Stoos, C.; Jagadesh, S.; Nguyen, C. A rare case of syndrome of inappropriate anti-diuretic hormone in non-small cell lung cancer presenting as superior vena cava syndrome. Cureus, 2019, 11(6), e4861.
[http://dx.doi.org/10.7759/cureus.4861] [PMID: 31410343]
[9]
Sugihara, H. Review on recent topics in hypophysitis. J. Nippon Med. Sch., 2017, 84(5), 201-208.
[http://dx.doi.org/10.1272/jnms.84.201] [PMID: 29142180]
[10]
Espiard, S.; Drougat, L.; Libé, R.; Assié, G.; Perlemoine, K.; Guignat, L.; Barrande, G.; Brucker-Davis, F.; Doullay, F.; Lopez, S.; Sonnet, E.; Torremocha, F.; Pinsard, D.; Chabbert-Buffet, N.; Raffin-Sanson, M.L.; Groussin, L.; Borson-Chazot, F.; Coste, J.; Bertagna, X.; Stratakis, C.A.; Beuschlein, F.; Ragazzon, B.; Bertherat, J. ARMC5 mutations in a large cohort of primary macronodular adrenal hyperplasia: Clinical and functional consequences. J. Clin. Endocrinol. Metab., 2015, 100(6), E926-E935.
[http://dx.doi.org/10.1210/jc.2014-4204] [PMID: 25853793]
[11]
Assié, G.; Libé, R.; Espiard, S.; Rizk-Rabin, M.; Guimier, A.; Luscap, W.; Barreau, O.; Lefèvre, L.; Sibony, M.; Guignat, L.; Rodriguez, S.; Perlemoine, K.; René-Corail, F.; Letourneur, F.; Trabulsi, B.; Poussier, A.; Chabbert-Buffet, N.; Borson-Chazot, F.; Groussin, L.; Bertagna, X.; Stratakis, C.A.; Ragazzon, B.; Bertherat, J. ARMC5 mutations in macronodular adrenal hyperplasia with Cushing’s syndrome. N. Engl. J. Med., 2013, 369(22), 2105-2114.
[http://dx.doi.org/10.1056/NEJMoa1304603] [PMID: 24283224]
[12]
Shao, J.; Wang, C.; Ren, P.; Jiang, Y.; Tian, P.; Li, W. Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer. Biosci. Rep., 2020, 40(5), BSR20192347.
[http://dx.doi.org/10.1042/BSR20192347] [PMID: 32315071]
[13]
Kubo, T.; Watanabe, H.; Ninomiya, K.; Kudo, K.; Minami, D.; Murakami, E.; Ochi, N.; Ninomiya, T.; Harada, D.; Yasugi, M.; Ichihara, E.; Ohashi, K.; Rai, K.; Fujiwara, K.; Hotta, K.; Tabata, M.; Maeda, Y.; Kiura, K. Immune checkpoint inhibitor efficacy and safety in older non-small cell lung cancer patients. Jpn. J. Clin. Oncol., 2020, 50(12), 1447-1453.
[http://dx.doi.org/10.1093/jjco/hyaa152] [PMID: 32869100]
[14]
Ho, A.K.; Ho, A.M.H.; Cooksley, T.; Nguyen, G.; Erb, J.; Mizubuti, G.B. Immune-related adverse events associated with immune checkpoint inhibitor therapy. Anesth. Analg., 2021, 132(2), 374-383.
[http://dx.doi.org/10.1213/ANE.0000000000005029] [PMID: 33009134]
[15]
Del Rivero, J.; Cordes, L.M.; Klubo-Gwiezdzinska, J.; Madan, R.A.; Nieman, L.K.; Gulley, J.L. Endocrine-related adverse events related to immune checkpoint inhibitors: Proposed algorithms for management. Oncologist, 2020, 25(4), 290-300.
[http://dx.doi.org/10.1634/theoncologist.2018-0470] [PMID: 32297436]
[16]
Riudavets, M.; Mosquera, J.; Garcia-Campelo, R.; Serra, J.; Anguera, G.; Gallardo, P.; Sullivan, I.; Barba, A.; del Carpio, L.; Barnadas, A.; Gich, I.; Majem, M. Immune-related adverse events and corticosteroid use for cancer-related symptoms are associated with efficacy in patients with non-small cell lung cancer receiving Anti-PD-(L)1 blockade agents. Front. Oncol., 2020, 10, 1677.
[http://dx.doi.org/10.3389/fonc.2020.01677] [PMID: 33014837]
[17]
Elia, G.; Ferrari, S.M.; Galdiero, M.R.; Ragusa, F.; Paparo, S.R.; Ruffilli, I.; Varricchi, G.; Fallahi, P.; Antonelli, A. New insight in endocrine-related adverse events associated to immune checkpoint blockade. Best Pract. Res. Clin. Endocrinol. Metab., 2020, 34(1), 101370.
[http://dx.doi.org/10.1016/j.beem.2019.101370] [PMID: 31983543]
[18]
Barroso-Sousa, R.; Barry, W.T.; Garrido-Castro, A.C.; Hodi, F.S.; Min, L.; Krop, I.E.; Tolaney, S.M. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens. JAMA Oncol., 2018, 4(2), 173-182.
[http://dx.doi.org/10.1001/jamaoncol.2017.3064] [PMID: 28973656]
[19]
Byun, D.J.; Wolchok, J.D.; Rosenberg, L.M.; Girotra, M. Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathies. Nat. Rev. Endocrinol., 2017, 13(4), 195-207.
[http://dx.doi.org/10.1038/nrendo.2016.205] [PMID: 28106152]
[20]
Jing, Y.; Liu, J.; Ye, Y.; Pan, L.; Deng, H.; Wang, Y.; Yang, Y.; Diao, L.; Lin, S.H.; Mills, G.B.; Zhuang, G.; Xue, X.; Han, L. Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy. Nat. Commun., 2020, 11(1), 4946.
[http://dx.doi.org/10.1038/s41467-020-18742-9] [PMID: 33009409]
[21]
Joshi, M.N.; Whitelaw, B.C.; Palomar, M.T.P.; Wu, Y.; Carroll, P.V. Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: Clinical review. Clin. Endocrinol., 2016, 85(3), 331-339.
[http://dx.doi.org/10.1111/cen.13063] [PMID: 26998595]
[22]
Joshi, M.N.; Whitelaw, B.C.; Carroll, P.V. Mechanisms in endocrinology: Hypophysitis: diagnosis and treatment. Eur. J. Endocrinol., 2018, 179(3), R151-R163.
[http://dx.doi.org/10.1530/EJE-17-0009] [PMID: 29880706]
[23]
Nada, A.; Bhat, R.; Cousins, J. Magnetic resonance imaging criteria of immune checkpoint inhibitor-induced hypophysitis. Curr. Probl. Cancer, 2021, 45(1), 100644.
[http://dx.doi.org/10.1016/j.currproblcancer.2020.100644] [PMID: 32888700]
[24]
Champiat, S.; Lambotte, O.; Barreau, E.; Belkhir, R.; Berdelou, A.; Carbonnel, F.; Cauquil, C.; Chanson, P.; Collins, M.; Durrbach, A.; Ederhy, S.; Feuillet, S.; François, H.; Lazarovici, J.; Le Pavec, J.; De Martin, E.; Mateus, C.; Michot, J.M.; Samuel, D.; Soria, J.C.; Robert, C.; Eggermont, A.; Marabelle, A. Management of immune checkpoint blockade dysimmune toxicities: A collaborative position paper. Ann. Oncol., 2016, 27(4), 559-574.
[http://dx.doi.org/10.1093/annonc/mdv623] [PMID: 26715621]
[25]
Higham, C.E.; Olsson-Brown, A.; Carroll, P.; Cooksley, T.; Larkin, J.; Lorigan, P.; Morganstein, D.; Trainer, P.J. Society for endocrinology endocrine emergency guidance: Acute management of the endocrine complications of checkpoint inhibitor therapy. Endocr. Connect., 2018, 7(7), G1-G7.
[http://dx.doi.org/10.1530/EC-18-0068] [PMID: 29930025]
[26]
Lin, C.H.; Chen, K.H.; Chen, K.Y.; Shih, S.R.; Lu, J.Y. Immune checkpoint inhibitor therapy-induced hypophysitis ∼ a case series of Taiwanese patients. J. Formos. Med. Assoc., 2019, 118(1), 524-529.
[http://dx.doi.org/10.1016/j.jfma.2018.07.014] [PMID: 30104119]
[27]
Morgado, M.; Plácido, A.; Morgado, S.; Roque, F. Management of the adverse effects of immune checkpoint inhibitors. Vaccines, 2020, 8(4), 575.
[http://dx.doi.org/10.3390/vaccines8040575] [PMID: 33019641]
[28]
Pickwell-Smith, B.A.; So, A.C.P.; Board, R.E. Managing side effects of cancer immunotherapy for the acute physician. Br. J. Hosp. Med., 2018, 79(7), 372-377.
[http://dx.doi.org/10.12968/hmed.2018.79.7.372] [PMID: 29995540]